160 related articles for article (PubMed ID: 34724226)
1. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Cousin S; Blay JY; Garcia IB; de Bono JS; Le Tourneau C; Moreno V; Trigo J; Hann CL; Azad AA; Im SA; Cassier PA; French CA; Italiano A; Keedy VL; Plummer R; Sablin MP; Hemming ML; Ferron-Brady G; Wyce A; Khaled A; Datta A; Foley SW; McCabe MT; Wu Y; Horner T; Kremer BE; Dhar A; O'Dwyer PJ; Shapiro GI; Piha-Paul SA
Int J Cancer; 2022 Mar; 150(6):993-1006. PubMed ID: 34724226
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Piha-Paul SA; Hann CL; French CA; Cousin S; Braña I; Cassier PA; Moreno V; de Bono JS; Harward SD; Ferron-Brady G; Barbash O; Wyce A; Wu Y; Horner T; Annan M; Parr NJ; Prinjha RK; Carpenter CL; Hilton J; Hong DS; Haas NB; Markowski MC; Dhar A; O'Dwyer PJ; Shapiro GI
JNCI Cancer Spectr; 2020 Apr; 4(2):pkz093. PubMed ID: 32328561
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model.
Krishnatry AS; Voelkner A; Dhar A; Prohn M; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):709-722. PubMed ID: 33955700
[TBL] [Abstract][Full Text] [Related]
4. Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors.
Krishnatry AS; Hanze E; Bergsma T; Dhar A; Prohn M; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):556-568. PubMed ID: 34648693
[TBL] [Abstract][Full Text] [Related]
5. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
Dawson MA; Borthakur G; Huntly BJP; Karadimitris A; Alegre A; Chaidos A; Vogl DT; Pollyea DA; Davies FE; Morgan GJ; Glass JL; Kamdar M; Mateos MV; Tovar N; Yeh P; Delgado RG; Basheer F; Marando L; Gallipoli P; Wyce A; Krishnatry AS; Barbash O; Bakirtzi E; Ferron-Brady G; Karpinich NO; McCabe MT; Foley SW; Horner T; Dhar A; Kremer BE; Dickinson M
Clin Cancer Res; 2023 Feb; 29(4):711-722. PubMed ID: 36350312
[TBL] [Abstract][Full Text] [Related]
6. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract][Full Text] [Related]
7. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
[TBL] [Abstract][Full Text] [Related]
8. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
Postel-Vinay S; Herbschleb K; Massard C; Woodcock V; Soria JC; Walter AO; Ewerton F; Poelman M; Benson N; Ocker M; Wilkinson G; Middleton M
Eur J Cancer; 2019 Mar; 109():103-110. PubMed ID: 30711772
[TBL] [Abstract][Full Text] [Related]
9. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
[TBL] [Abstract][Full Text] [Related]
10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
11. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Aghajanian C; Bell-McGuinn KM; Burris HA; Siu LL; Stayner LA; Wheler JJ; Hong DS; Kurkjian C; Pant S; Santiago-Walker A; Gauvin JL; Antal JM; Opalinska JB; Morris SR; Infante JR
Invest New Drugs; 2018 Dec; 36(6):1016-1025. PubMed ID: 29611022
[TBL] [Abstract][Full Text] [Related]
12. A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.
Mateo J; Ganji G; Lemech C; Burris HA; Han SW; Swales K; Decordova S; DeYoung MP; Smith DA; Kalyana-Sundaram S; Wu J; Motwani M; Kumar R; Tolson JM; Rha SY; Chung HC; Eder JP; Sharma S; Bang YJ; Infante JR; Yan L; de Bono JS; Arkenau HT
Clin Cancer Res; 2017 Oct; 23(19):5981-5992. PubMed ID: 28645941
[No Abstract] [Full Text] [Related]
13. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
15. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
Ameratunga M; Braña I; Bono P; Postel-Vinay S; Plummer R; Aspegren J; Korjamo T; Snapir A; de Bono JS
Br J Cancer; 2020 Dec; 123(12):1730-1736. PubMed ID: 32989226
[TBL] [Abstract][Full Text] [Related]
16. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
18. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
19. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Piha-Paul SA; Sachdev JC; Barve M; LoRusso P; Szmulewitz R; Patel SP; Lara PN; Chen X; Hu B; Freise KJ; Modi D; Sood A; Hutti JE; Wolff J; O'Neil BH
Clin Cancer Res; 2019 Nov; 25(21):6309-6319. PubMed ID: 31420359
[TBL] [Abstract][Full Text] [Related]
20. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Lewin J; Soria JC; Stathis A; Delord JP; Peters S; Awada A; Aftimos PG; Bekradda M; Rezai K; Zeng Z; Hussain A; Perez S; Siu LL; Massard C
J Clin Oncol; 2018 Oct; 36(30):3007-3014. PubMed ID: 29733771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]